Generic Oncology Drugs Market Size, Growth and Forecast By 2021-26


According to IMARC Group’s latest report, titled “Generic Oncology Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026.’ the global generic oncology drugs market reached a value of US$ 27.3 Billion in 2020.A generic drug refers to a pharmaceutical medication with the same chemical substances as a drug that was earlier protected by chemical patents, which have since expired. Generic oncology drugs assist in controlling, shrinking, and destroying the cancer cells present in the human body. They include the same active ingredients as the branded drug and also offer the same performance, quality, strength, etc. Generic oncology drugs are utilized by hospitals and patients across the globe to yield the same therapeutic effects at a fraction of the branded price.

We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report

Request for a PDF sample of this report:

The growing prevalence of cancer is one of the key factors driving the generic oncology drugs market. In line with this, increasing awareness about the benefits of early cancer diagnosis and adopting preventive measures is further catalyzing the market growth. Moreover, the inflating need for affordable and cost-effective drugs, on account of the high healthcare expenses associated with full-length cancer treatment, is acting as another significant growth-inducing factor. Besides this, the accelerating trend of patent expiration of key blockbuster drugs is augmenting the global market. Additionally, the launch of favorable initiatives by government bodies aimed at developing and promoting improved and effective generic drugs is also positively influencing the market growth. Apart from this, the rising investments in research and development (R&D) activities to reduce the cost of cancer treatments and enable cancer diagnosis at earlier stages are anticipated to fuel the generic oncology drugs market over the forecasted period. Looking forward, IMARC Group expects the market to reach a value of US$ 46.8 Billion by 2026.

Regional Insights:

North America


Asia Pacific

Middle East and Africa

Latin America

Ask Analyst for Customization and Explore full report with TOC & List of Figures

We are updating our reports, If you want latest primary and secondary data (2021-2026) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours.

Key highlights of the report:                                                           

  • Market Performance (2015-2020)
  • Market Outlook (2022-2027)
  • Market Trends
  • Market Drivers and Success Factors
  • The Impact of COVID-19 on the Global Market
  • Value Chain Analysis
  • Structure of the Global Market
  • Comprehensive mapping of the competitive landscape

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us                                                                      

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us


30 N Gould St Ste R

Sheridan, WY 82801 USA – Wyoming


Tel No:(D) +91 120 433 0800

Americas: – +1 631 791 1145 | Africa and Europe: – +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800